{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:49:35Z","timestamp":1781534975322,"version":"3.54.5"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The<jats:italic>Mycobacterium<\/jats:italic><jats:italic>abscessus<\/jats:italic>complex (MABC) is a group of acid-fast, rapidly dividing non-tuberculous mycobacteria (NTM) that include a number of clinically important subspecies, including<jats:italic>M.<\/jats:italic><jats:italic>abscessus,<\/jats:italic><jats:italic>M.<\/jats:italic><jats:italic>bolletii,<\/jats:italic>and<jats:italic>M.<\/jats:italic><jats:italic>massiliense<\/jats:italic>. These organisms are prevalent in the environment and are primarily associated with human pulmonary or skin and skin structure infections (SSSI) but may cause more deep-seeded disseminated infections and bacteremia in the immunocompromised. Importantly, these NTM are resistant to most first-line anti-tuberculous agents and, due to intrinsic or acquired resistance, exhibit exceedingly low, variable, and geographically distinct susceptibilities to commonly used antibacterial agents including older tetracyclines, macrolides, aminoglycosides, cephalosporins, carbapenems, and sulfamethoxazole-trimethoprim. Omadacycline is a novel third-generation member of the tetracycline family of antibacterials that has recently been demonstrated to have potent anti-NTM effects and clinical efficacy against MABC, including<jats:italic>M.<\/jats:italic><jats:italic>abscessus.<\/jats:italic>The purpose of this review is to present a comprehensive and up-to-date assessment on the body of literature on the role of omadacycline for<jats:italic>M.<\/jats:italic><jats:italic>abscessus<\/jats:italic>infections. Specifically, the in vitro and in vivo microbiology, mechanisms of action, mechanisms of resistance, clinical pharmacokinetics, clinical efficacy, adverse effects, dosage and administration, and place in therapy of omadacycline in management of<jats:italic>M.<\/jats:italic><jats:italic>abscessus<\/jats:italic>infections will be detailed.<\/jats:p>","DOI":"10.1186\/s12879-022-07857-7","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T08:04:09Z","timestamp":1669190649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use"],"prefix":"10.1186","volume":"22","author":[{"given":"Ashley R.","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8893-4339","authenticated-orcid":false,"given":"Nader H.","family":"Moniri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"7857_CR1","doi-asserted-by":"crossref","unstructured":"Abdelaal HFM et al. Mycobacterium abscessus: it's complex. Microorganisms. 2022;10(7):1454.","DOI":"10.3390\/microorganisms10071454"},{"key":"7857_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1471-2334-13-241","volume":"13","author":"R Thomson","year":"2013","unstructured":"Thomson R, et al. Mycobacterium abscessus isolated from municipal water\u2014a potential source of human infection. BMC Infect Dis. 2013;13:241.","journal-title":"BMC Infect Dis"},{"key":"7857_CR3","doi-asserted-by":"crossref","unstructured":"Lopeman RC et al. Mycobacterium abscessus: environmental bacterium turned clinical nightmare. Microorganisms. 2019;7(3):90.","DOI":"10.3390\/microorganisms7030090"},{"issue":"8","key":"7857_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1164\/rccm.201807-1273PP","volume":"199","author":"S Daniel-Wayman","year":"2019","unstructured":"Daniel-Wayman S, et al. Advancing translational science for pulmonary nontuberculous Mycobacterial infections. A road map for research. Am J Respir Crit Care Med. 2019;199(8):947\u201351.","journal-title":"Am J Respir Crit Care Med"},{"key":"7857_CR5","doi-asserted-by":"crossref","unstructured":"Cowman S, et al. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J. 2019;54(1):1900250.","DOI":"10.1183\/13993003.00250-2019"},{"issue":"9","key":"7857_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/17476348.2019.1638765","volume":"13","author":"YS Kwon","year":"2019","unstructured":"Kwon YS, Daley CL, Koh WJ. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches. Expert Rev Respir Med. 2019;13(9):851\u201361.","journal-title":"Expert Rev Respir Med"},{"issue":"5","key":"7857_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.medcli.2017.07.010","volume":"150","author":"LM Carro","year":"2018","unstructured":"Carro LM, Herranz EB, Royo RN. Respiratory infections due to nontuberculous mycobacterias. Med Clin. 2018;150(5):191\u20137. https:\/\/doi.org\/10.1016\/j.medcli.2017.07.010.","journal-title":"Med Clin"},{"key":"7857_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00069-18","author":"C Franco-Paredes","year":"2018","unstructured":"Franco-Paredes C, et al. Cutaneous mycobacterial infections. Clin Microbiol Rev. 2018. https:\/\/doi.org\/10.1128\/CMR.00069-18.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"7857_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.det.2015.03.017","volume":"33","author":"TM Gonzalez-Santiago","year":"2015","unstructured":"Gonzalez-Santiago TM, Drage LA. Nontuberculous mycobacteria: skin and soft tissue infections. Dermatol Clin. 2015;33(3):563\u201377.","journal-title":"Dermatol Clin"},{"issue":"3","key":"7857_CR10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4103\/ijmy.ijmy_110_21","volume":"10","author":"C Kumar","year":"2021","unstructured":"Kumar C, et al. Skin and soft-tissue infections due to rapidly growing mycobacteria: an overview. Int J Mycobacteriol. 2021;10(3):293\u2013300.","journal-title":"Int J Mycobacteriol"},{"issue":"4","key":"7857_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11908-018-0611-3","volume":"20","author":"EA Misch","year":"2018","unstructured":"Misch EA, Saddler C, Davis JM. Skin and soft tissue infections due to nontuberculous Mycobacteria. Curr Infect Dis Rep. 2018;20(4):6.","journal-title":"Curr Infect Dis Rep"},{"issue":"4","key":"7857_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.amjms.2016.02.009","volume":"351","author":"A Baidya","year":"2016","unstructured":"Baidya A, et al. Mycobacterium abscessus as a cause of chronic meningitis: a rare clinical entity. Am J Med Sci. 2016;351(4):437\u20139.","journal-title":"Am J Med Sci"},{"issue":"5","key":"7857_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s15010-018-1141-5","volume":"46","author":"F Giovannenze","year":"2018","unstructured":"Giovannenze F, et al. Incidental intraoperative diagnosis of Mycobacterium abscessus meningeal infection: a case report and review of the literature. Infection. 2018;46(5):591\u20137.","journal-title":"Infection"},{"issue":"6","key":"7857_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S1473-3099(08)70127-0","volume":"8","author":"NJ Talati","year":"2008","unstructured":"Talati NJ, et al. Spectrum of CNS disease caused by rapidly growing mycobacteria. Lancet Infect Dis. 2008;8(6):390\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"7857_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/jac\/dkr420","volume":"67","author":"MR Lee","year":"2012","unstructured":"Lee MR, et al. CNS infections caused by Mycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates. J Antimicrob Chemother. 2012;67(1):222\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"7857_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116236","volume":"10","author":"HS Chu","year":"2015","unstructured":"Chu HS, et al. Nontuberculous mycobacterial ocular infections\u2013comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense. PLoS ONE. 2015;10(1): e0116236.","journal-title":"PLoS ONE"},{"issue":"2","key":"7857_CR17","first-page":"160","volume":"17","author":"R Dhiman","year":"2022","unstructured":"Dhiman R, et al. Clinico-microbiological profile of nontuberculous Mycobacterial Keratitis. J Ophthalmic Vis Res. 2022;17(2):160\u20139.","journal-title":"J Ophthalmic Vis Res"},{"issue":"5","key":"7857_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1442-9071.2011.02679.x","volume":"40","author":"DO Girgis","year":"2012","unstructured":"Girgis DO, Karp CL, Miller D. Ocular infections caused by non-tuberculous mycobacteria: update on epidemiology and management. Clin Exp Ophthalmol. 2012;40(5):467\u201375.","journal-title":"Clin Exp Ophthalmol"},{"key":"7857_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100971","volume":"20","author":"AY Kim","year":"2020","unstructured":"Kim AY, et al. Management of nontuberculous mycobacterial infections of the eye and orbit: a retrospective case series. Am J Ophthalmol Case Rep. 2020;20: 100971.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"7857_CR20","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1186\/s12879-020-05606-2","volume":"20","author":"W Pinitpuwadol","year":"2020","unstructured":"Pinitpuwadol W, et al. Nontuberculous mycobacterial endophthalmitis: case series and review of literature. BMC Infect Dis. 2020;20(1):877.","journal-title":"BMC Infect Dis"},{"key":"7857_CR21","first-page":"837","volume":"8","author":"N Venkateswaran","year":"2014","unstructured":"Venkateswaran N, et al. Recurrent nontuberculous mycobacterial endophthalmitis: a diagnostic conundrum. Clin Ophthalmol. 2014;8:837\u201342.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"7857_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0732-8893(00)00211-X","volume":"39","author":"PS Mueller","year":"2001","unstructured":"Mueller PS, Edson RS. Disseminated Mycobacterium abscessus infection manifesting as fever of unknown origin and intra-abdominal lymphadenitis: case report and literature review. Diagn Microbiol Infect Dis. 2001;39(1):33\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"7857_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/clinids\/5.4.657","volume":"5","author":"RJ Wallace Jr","year":"1983","unstructured":"Wallace RJ Jr, et al. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis. 1983;5(4):657\u201379.","journal-title":"Rev Infect Dis"},{"issue":"2","key":"7857_CR24","first-page":"295","volume":"22","author":"SA Weerakoon","year":"2022","unstructured":"Weerakoon SA, et al. Early disseminated Mycobacterium abscessus complex infection in an infant with coexisting cystic fibrosis and progressive familial intrahepatic cholestasis: case report and literature review. Sultan Qaboos Univ Med J. 2022;22(2):295\u20139.","journal-title":"Sultan Qaboos Univ Med J"},{"issue":"1","key":"7857_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5414\/CNP63057","volume":"63","author":"VC Wu","year":"2005","unstructured":"Wu VC, et al. Disseminated mycobacterium abscessus infection in a hemodialysis patient with acquired reactive perforating collagenosis\u2014a case study and literature review. Clin Nephrol. 2005;63(1):57\u201360.","journal-title":"Clin Nephrol"},{"issue":"1","key":"7857_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccm.2014.11.002","volume":"36","author":"E Henkle","year":"2015","unstructured":"Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med. 2015;36(1):91\u20139.","journal-title":"Clin Chest Med"},{"issue":"3","key":"7857_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/thoraxjnl-2012-201772","volume":"68","author":"C Andr\u00e9jak","year":"2013","unstructured":"Andr\u00e9jak C, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68(3):256\u201362.","journal-title":"Thorax"},{"issue":"7","key":"7857_CR28","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","volume":"182","author":"DR Prevots","year":"2010","unstructured":"Prevots DR, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"7857_CR29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1055\/s-0039-1693706","volume":"40","author":"CJ Richards","year":"2019","unstructured":"Richards CJ, Olivier KN. Nontuberculous mycobacteria in cystic fibrosis. Semin Respir Crit Care Med. 2019;40(6):737\u201350.","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"7857_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.thorsurg.2018.09.008","volume":"29","author":"SL Martiniano","year":"2019","unstructured":"Martiniano SL, Nick JA, Daley CL. Nontuberculous mycobacterial infections in cystic fibrosis. Thorac Surg Clin. 2019;29(1):95\u2013108.","journal-title":"Thorac Surg Clin"},{"issue":"2","key":"7857_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1378\/chest.15-0676","volume":"149","author":"EL Salsgiver","year":"2016","unstructured":"Salsgiver EL, et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest. 2016;149(2):390\u2013400.","journal-title":"Chest"},{"issue":"1","key":"7857_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12890-019-0781-2","volume":"19","author":"D Stephenson","year":"2019","unstructured":"Stephenson D, et al. An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation. BMC Pulm Med. 2019;19(1):19.","journal-title":"BMC Pulm Med"},{"issue":"7","key":"7857_CR33","first-page":"207","volume":"107","author":"SG Chong","year":"2014","unstructured":"Chong SG, et al. Pulmonary non-tuberculous mycobacteria in a general respiratory population. Ir Med J. 2014;107(7):207\u20139.","journal-title":"Ir Med J"},{"issue":"3","key":"7857_CR34","first-page":"393","volume":"19","author":"KG de Mello","year":"2013","unstructured":"de Mello KG, et al. Clinical and therapeutic features of pulmonary nontuberculous mycobacterial disease, Brazil, 1993\u20132011. Emerg Infect Dis. 2013;19(3):393\u20139.","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"7857_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10096-020-04026-z","volume":"40","author":"K Fujiwara","year":"2021","unstructured":"Fujiwara K, et al. Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease. Eur J Clin Microbiol Infect Dis. 2021;40(2):247\u201354.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"7857_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.912651","volume":"10","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, et al. Risk factors and mental health status in patients with non-tuberculous mycobacterial lung disease: a single center retrospective study. Front Public Health. 2022;10: 912651.","journal-title":"Front Public Health"},{"issue":"Suppl 1","key":"7857_CR37","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jfma.2020.05.028","volume":"119","author":"YW Weng","year":"2020","unstructured":"Weng YW, et al. Treatment for Mycobacterium abscessus complex-lung disease. J Formos Med Assoc. 2020;119(Suppl 1):S58\u201366.","journal-title":"J Formos Med Assoc"},{"key":"7857_CR38","doi-asserted-by":"crossref","unstructured":"Broncano-Lavado A, et al. Alternatives to antibiotics against Mycobacterium abscessus. Antibiotics (Basel). 2022;11(10):1322.","DOI":"10.3390\/antibiotics11101322"},{"key":"7857_CR39","doi-asserted-by":"crossref","unstructured":"Saxena S, Spaink HP, Forn-Cun\u00ed G. Drug resistance in nontuberculous mycobacteria: mechanisms and models. Biology (Basel). 2021;10(2):96.","DOI":"10.3390\/biology10020096"},{"key":"7857_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.743126","volume":"12","author":"JM Belardinelli","year":"2021","unstructured":"Belardinelli JM, et al. Unique features of Mycobacterium abscessus biofilms formed in synthetic cystic fibrosis medium. Front Microbiol. 2021;12: 743126.","journal-title":"Front Microbiol"},{"issue":"6","key":"7857_CR41","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1164\/rccm.201508-1586IM","volume":"193","author":"KP Fennelly","year":"2016","unstructured":"Fennelly KP, et al. Biofilm formation by Mycobacterium abscessus in a lung cavity. Am J Respir Crit Care Med. 2016;193(6):692\u20133.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"7857_CR42","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1183\/13993003.01102-2015","volume":"46","author":"T Qvist","year":"2015","unstructured":"Qvist T, et al. Chronic pulmonary disease with Mycobacterium abscessus complex is a biofilm infection. Eur Respir J. 2015;46(6):1823\u20136.","journal-title":"Eur Respir J"},{"issue":"1","key":"7857_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1128\/IAI.00820-13","volume":"82","author":"SJ Rose","year":"2014","unstructured":"Rose SJ, Bermudez LE. Mycobacterium avium biofilm attenuates mononuclear phagocyte function by triggering hyperstimulation and apoptosis during early infection. Infect Immun. 2014;82(1):405\u201312.","journal-title":"Infect Immun"},{"issue":"2","key":"7857_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057402","volume":"8","author":"KC Malcolm","year":"2013","unstructured":"Malcolm KC, et al. Mycobacterium abscessus induces a limited pattern of neutrophil activation that promotes pathogen survival. PLoS ONE. 2013;8(2): e57402.","journal-title":"PLoS ONE"},{"issue":"1","key":"7857_CR45","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1038\/s41598-021-84525-x","volume":"11","author":"ES Gloag","year":"2021","unstructured":"Gloag ES, et al. Mycobacterium abscessus biofilms have viscoelastic properties which may contribute to their recalcitrance in chronic pulmonary infections. Sci Rep. 2021;11(1):5020.","journal-title":"Sci Rep"},{"issue":"10","key":"7857_CR46","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/s41564-021-00963-3","volume":"6","author":"C Ruis","year":"2021","unstructured":"Ruis C, et al. Dissemination of Mycobacterium abscessus via global transmission networks. Nat Microbiol. 2021;6(10):1279\u201388.","journal-title":"Nat Microbiol"},{"issue":"6","key":"7857_CR47","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s12275-008-0102-6","volume":"46","author":"JH Shin","year":"2008","unstructured":"Shin JH, et al. Targeting the rpoB gene using nested PCR-restriction fragment length polymorphism for identification of nontuberculous mycobacteria in hospital tap water. J Microbiol. 2008;46(6):608\u201314.","journal-title":"J Microbiol"},{"issue":"9","key":"7857_CR48","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1086\/661282","volume":"32","author":"MM Williams","year":"2011","unstructured":"Williams MM, et al. Point-of-use membrane filtration and hyperchlorination to prevent patient exposure to rapidly growing mycobacteria in the potable water supply of a skilled nursing facility. Infect Control Hosp Epidemiol. 2011;32(9):837\u201344.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"7857_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/apm.12153","volume":"122","author":"E Torvinen","year":"2014","unstructured":"Torvinen E, et al. Mycobacteria in Finnish cooling tower waters. APMIS. 2014;122(4):353\u20138.","journal-title":"APMIS"},{"issue":"14","key":"7857_CR50","doi-asserted-by":"publisher","first-page":"8432","DOI":"10.1021\/acs.est.5b00555","volume":"49","author":"CK Gomez-Smith","year":"2015","unstructured":"Gomez-Smith CK, LaPara TM, Hozalski RM. Sulfate reducing bacteria and mycobacteria dominate the biofilm communities in a chloraminated drinking water distribution system. Environ Sci Technol. 2015;49(14):8432\u201340.","journal-title":"Environ Sci Technol"},{"issue":"12","key":"7857_CR51","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1099\/mic.0.000857","volume":"165","author":"M Davarpanah","year":"2019","unstructured":"Davarpanah M, Azadi D, Shojaei H. Prevalence and molecular characterization of non-tuberculous mycobacteria in hospital soil and dust of a developing country, Iran. Microbiology (Reading). 2019;165(12):1306\u201314.","journal-title":"Microbiology (Reading)"},{"key":"7857_CR52","doi-asserted-by":"crossref","unstructured":"Glickman CM, et al. Assessment of soil features on the growth of environmental nontuberculous mycobacterial isolates from Hawai'i. Appl Environ Microbiol. 2020;86(21):e00121-20.","DOI":"10.1128\/AEM.00121-20"},{"issue":"9","key":"7857_CR53","doi-asserted-by":"publisher","DOI":"10.1128\/aem.00018-22","volume":"88","author":"AW Parsons","year":"2022","unstructured":"Parsons AW, et al. Soil properties and moisture synergistically influence nontuberculous mycobacterial prevalence in natural environments of Hawai\u2019i. Appl Environ Microbiol. 2022;88(9): e0001822.","journal-title":"Appl Environ Microbiol"},{"key":"7857_CR54","doi-asserted-by":"crossref","unstructured":"Malcolm KC, et al. Mycobacterium abscessus displays fitness for fomite transmission. Appl Environ Microbiol. 2017;83(19):e00562-17.","DOI":"10.1128\/AEM.00562-17"},{"issue":"2","key":"7857_CR55","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.01242-13","volume":"58","author":"AB Macone","year":"2014","unstructured":"Macone AB, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127\u201335.","journal-title":"Antimicrob Agents Chemother"},{"key":"7857_CR56","doi-asserted-by":"crossref","unstructured":"Kaushik A, et al. In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63(6):e00470-19.","DOI":"10.1128\/AAC.00470-19"},{"key":"7857_CR57","doi-asserted-by":"crossref","unstructured":"Shoen C, et al. In vitro activities of omadacycline against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2019;63(5):e02522-18.","DOI":"10.1128\/AAC.02522-18"},{"issue":"10","key":"7857_CR58","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/jac\/dkz267","volume":"74","author":"HI Bax","year":"2019","unstructured":"Bax HI, et al. Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus. J Antimicrob Chemother. 2019;74(10):2930\u20133.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"7857_CR59","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01704-21","volume":"66","author":"DA Nicklas","year":"2022","unstructured":"Nicklas DA, et al. Potency of omadacycline against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection. Antimicrob Agents Chemother. 2022;66(1): e0170421.","journal-title":"Antimicrob Agents Chemother"},{"key":"7857_CR60","doi-asserted-by":"crossref","unstructured":"Brown-Elliott BA, Wallace RJ, Jr. In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria. Antimicrob Agents Chemother. 2021;65(3):e01947-20.","DOI":"10.1128\/AAC.01947-20"},{"key":"7857_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.790767","volume":"12","author":"BT Bich Hanh","year":"2021","unstructured":"Bich Hanh BT, et al. Omadacycline potentiates clarithromycin activity against Mycobacterium abscessus. Front Pharmacol. 2021;12: 790767.","journal-title":"Front Pharmacol"},{"key":"7857_CR62","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00018-17","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, et al. Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010\u20132011. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.00018-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"7857_CR63","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/cid\/ciz395","volume":"69","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Steenbergen J, Zhanel GG. Microbiology and preclinical review of omadacycline. Clin Infect Dis. 2019;69(Suppl 1):S6-s15.","journal-title":"Clin Infect Dis"},{"key":"7857_CR64","doi-asserted-by":"publisher","unstructured":"Pfaller MA, et al. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018. Antimicrob Agents Chemother, 2020. https:\/\/doi.org\/10.1128\/AAC.02488-19.","DOI":"10.1128\/AAC.02488-19"},{"key":"7857_CR65","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","volume":"11","author":"S Villano","year":"2016","unstructured":"Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11:1421\u201334.","journal-title":"Future Microbiol"},{"issue":"12","key":"7857_CR66","doi-asserted-by":"publisher","first-page":"7502","DOI":"10.1128\/AAC.01734-16","volume":"60","author":"KB Waites","year":"2016","unstructured":"Waites KB, et al. In vitro activities of omadacycline (PTK 0796) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother. 2016;60(12):7502\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"7857_CR67","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00047-18","author":"L Stapert","year":"2018","unstructured":"Stapert L, et al. In vitro activities of omadacycline and comparators against anaerobic bacteria. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.00047-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"7857_CR68","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1128\/AAC.01066-13","volume":"58","author":"MP Draper","year":"2014","unstructured":"Draper MP, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother. 2014;58(3):1279\u201383.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"7857_CR69","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1128\/AAC.01275-08","volume":"53","author":"KA Nash","year":"2009","unstructured":"Nash KA, Brown-Elliott BA, Wallace RJ. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009;53(4):1367\u201376.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"7857_CR70","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1128\/AAC.00861-10","volume":"55","author":"S Bastian","year":"2011","unstructured":"Bastian S, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus Group byerm(41) and rrl Sequencing. Antimicrob Agents Chemother. 2011;55(2):775\u201381.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"7857_CR71","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1164\/rccm.201111-2005OC","volume":"186","author":"GE Choi","year":"2012","unstructured":"Choi GE, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012;186(9):917\u201325.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"7857_CR72","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1086\/515328","volume":"177","author":"T Prammananan","year":"1998","unstructured":"Prammananan T, et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis. 1998;177(6):1573\u201381.","journal-title":"J Infect Dis"},{"issue":"8","key":"7857_CR73","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/jac\/dkr209","volume":"66","author":"R Nessar","year":"2011","unstructured":"Nessar R, et al. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J Antimicrob Chemother. 2011;66(8):1719\u201324.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"7857_CR74","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1093\/jac\/dku550","volume":"70","author":"FP Maurer","year":"2015","unstructured":"Maurer FP, et al. Aminoglycoside-modifying enzymes determine the innate susceptibility to aminoglycoside antibiotics in rapidly growing mycobacteria. J Antimicrob Chemother. 2015;70(5):1412\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"7857_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005660","volume":"4","author":"F Ripoll","year":"2009","unstructured":"Ripoll F, et al. Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS ONE. 2009;4(6): e5660.","journal-title":"PLoS ONE"},{"issue":"4","key":"7857_CR76","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1128\/CMR.000055-12","volume":"25","author":"BA Brown-Elliott","year":"2012","unstructured":"Brown-Elliott BA, Nash KA, Wallace RJ. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012;25(4):721\u2013721.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"7857_CR77","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1128\/JB.00606-10","volume":"193","author":"M Lavollay","year":"2011","unstructured":"Lavollay M, et al. The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L D-transpeptidases. J Bacteriol. 2011;193(3):778\u201382.","journal-title":"J Bacteriol"},{"issue":"9","key":"7857_CR78","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1128\/AAC.35.9.1937","volume":"35","author":"V Jarlier","year":"1991","unstructured":"Jarlier V, Gutmann L, Nikaido H. Interplay of cell wall barrier and beta-lactamase activity determines high resistance to beta-lactam antibiotics in Mycobacterium chelonae. Antimicrob Agents Chemother. 1991;35(9):1937\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"7857_CR79","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1128\/AAC.41.8.1721","volume":"41","author":"S Mukhopadhyay","year":"1997","unstructured":"Mukhopadhyay S, Chakrabarti P. Altered permeability and beta-lactam resistance in a mutant of Mycobacterium smegmatis. Antimicrob Agents Chemother. 1997;41(8):1721\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"7857_CR80","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1128\/AAC.36.5.1068","volume":"36","author":"L Fattorini","year":"1992","unstructured":"Fattorini L, et al. Resistance to beta-lactams in Mycobacterium fortuitum. Antimicrob Agents Chemother. 1992;36(5):1068\u201372.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"7857_CR81","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1128\/AAC.38.6.1408","volume":"38","author":"Y Pang","year":"1994","unstructured":"Pang Y, et al. Tetracycline resistance determinants in Mycobacterium and Streptomyces species. Antimicrob Agents Chemother. 1994;38(6):1408\u201312.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9 Pt 2","key":"7857_CR82","doi-asserted-by":"publisher","first-page":"219S","DOI":"10.1592\/phco.20.14.219S.35046","volume":"20","author":"SJ Projan","year":"2000","unstructured":"Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy. 2000;20(9 Pt 2):219S-223S; discussion 224S-228S.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"7857_CR83","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41429-020-00392-0","volume":"74","author":"E Portell-Buj","year":"2021","unstructured":"Portell-Buj E, et al. Comparison of two-drug combinations, amikacin\/tigecycline\/imipenem and amikacin\/tigecycline\/clarithromycin against Mycobacteroides abscessus subsp. abscessus using the in vitro time-kill assay. J Antibiot (Tokyo). 2021;74(4):285\u201390.","journal-title":"J Antibiot (Tokyo)"},{"key":"7857_CR84","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.2147\/IDR.S252485","volume":"13","author":"Y Guo","year":"2020","unstructured":"Guo Y, et al. Antimicrobial susceptibility of Mycobacterium abscessus complex clinical isolates from a Chinese Tertiary Hospital. Infect Drug Resist. 2020;13:2001\u201310.","journal-title":"Infect Drug Resist"},{"issue":"8","key":"7857_CR85","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","volume":"47","author":"J Flarakos","year":"2017","unstructured":"Flarakos J, et al. Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. Xenobiotica. 2017;47(8):682\u201396.","journal-title":"Xenobiotica"},{"key":"7857_CR86","unstructured":"Paratek Pharmaceuticals, I., Boston, MA, NUZYRA (Brand of omadacycline) [package insert]. 2021, Paratek Pharmaceuticals, Inc., Boston, MA."},{"issue":"12","key":"7857_CR87","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.1128\/AAC.01393-16","volume":"60","author":"H Sun","year":"2016","unstructured":"Sun H, et al. Randomized, open-label study of the pharmacokinetics and safety of oral and intravenous administration of omadacycline to healthy subjects. Antimicrob Agents Chemother. 2016;60(12):7431\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"7857_CR88","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1093\/cid\/ciz309","volume":"69","author":"KA Rodvold","year":"2019","unstructured":"Rodvold KA, Pai MP. Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline. Clin Infect Dis. 2019;69(Suppl 1):S16-s22.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"7857_CR89","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jcph.814","volume":"57","author":"E Tzanis","year":"2017","unstructured":"Tzanis E, et al. Effect of food on the bioavailability of omadacycline in healthy participants. J Clin Pharmacol. 2017;57(3):321\u20137.","journal-title":"J Clin Pharmacol"},{"key":"7857_CR90","doi-asserted-by":"crossref","unstructured":"Lin W, et al. Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-Omadacycline in rats. Antimicrob Agents Chemother. 2017; 61(1):e01784-16.","DOI":"10.1128\/AAC.01784-16"},{"key":"7857_CR91","doi-asserted-by":"crossref","unstructured":"Gotfried MH, et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother. 2017; 61(9):e01135-17.","DOI":"10.1128\/AAC.01135-17"},{"issue":"2","key":"7857_CR92","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jac\/dkl224","volume":"58","author":"KN Agwuh","year":"2006","unstructured":"Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256\u201365.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"7857_CR93","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1124\/dmd.107.015735","volume":"35","author":"M Hoffmann","year":"2007","unstructured":"Hoffmann M, et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos. 2007;35(9):1543\u201353.","journal-title":"Drug Metab Dispos"},{"key":"7857_CR94","doi-asserted-by":"crossref","unstructured":"Bundrant LA, et al. Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens. Antimicrob Agents Chemother. 2018; 62(2):e01487-17.","DOI":"10.1128\/AAC.01487-17"},{"key":"7857_CR95","doi-asserted-by":"crossref","unstructured":"Berg JK, et al. Pharmacokinetics and safety of omadacycline in subjects with impaired renal function. Antimicrob Agents Chemother. 2018; 62(2):e02057-17.","DOI":"10.1128\/AAC.02057-17"},{"key":"7857_CR96","doi-asserted-by":"crossref","unstructured":"Kovacs SJ, et al. An open-label study of the impact of hepatic impairment on the pharmacokinetics and safety of single oral and intravenous doses of omadacycline. Antimicrob Agents Chemother. 2020; 64(11):e01650-20.","DOI":"10.1128\/AAC.01650-20"},{"key":"7857_CR97","unstructured":"CLSI. Performance standards for antimicrobial susceptability testing, 32nd edn. CLSI Supplement M100. Wayne, PA. Clinical and Laboratory Standards Institute., 2022."},{"issue":"10","key":"7857_CR98","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1128\/AAC.46.10.3164-3167.2002","volume":"46","author":"RJ Wallace Jr","year":"2002","unstructured":"Wallace RJ Jr, et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother. 2002;46(10):3164\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"7857_CR99","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1684-1182(10)60063-1","volume":"43","author":"YC Huang","year":"2010","unstructured":"Huang YC, et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. J Microbiol Immunol Infect. 2010;43(5):401\u20136.","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"7857_CR100","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijantimicag.2012.10.021","volume":"41","author":"CW Huang","year":"2013","unstructured":"Huang CW, et al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. Int J Antimicrob Agents. 2013;41(3):218\u201323.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"7857_CR101","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1128\/AAC.03112-15","volume":"60","author":"BE Ferro","year":"2016","unstructured":"Ferro BE, et al. Tigecycline is highly efficacious against Mycobacterium abscessus pulmonary disease. Antimicrob Agents Chemother. 2016;60(5):2895\u2013900.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"7857_CR102","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1600-0463.2006.apm_390.x","volume":"114","author":"B Petrini","year":"2006","unstructured":"Petrini B. Mycobacterium abscessus: an emerging rapid-growing potential pathogen. APMIS. 2006;114(5):319\u201328.","journal-title":"APMIS"},{"issue":"7","key":"7857_CR103","volume":"11","author":"R Minhas","year":"2019","unstructured":"Minhas R, Sharma S, Kundu S. Utilizing the promise of omadacycline in a resistant, non-tubercular mycobacterial pulmonary infection. Cureus. 2019;11(7): e5112.","journal-title":"Cureus"},{"issue":"4","key":"7857_CR104","first-page":"610","volume":"33","author":"M Frizzell","year":"2020","unstructured":"Frizzell M, Carr E, Brust K. Omadacycline for treatment of Mycobacterium chelonae skin infection. Proc (Bayl Univ Med Cent). 2020;33(4):610\u20131.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"10","key":"7857_CR105","doi-asserted-by":"publisher","first-page":"ofaa415","DOI":"10.1093\/ofid\/ofaa415","volume":"7","author":"JC Pearson","year":"2020","unstructured":"Pearson JC, et al. Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series. Open Forum Infect Dis. 2020;7(10):ofaa415.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"7857_CR106","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab002","volume":"8","author":"T Morrisette","year":"2021","unstructured":"Morrisette T, et al. Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections. Open Forum Infect Dis. 2021;8(2): ofab002.","journal-title":"Open Forum Infect Dis"},{"key":"7857_CR107","doi-asserted-by":"crossref","unstructured":"Meir M, Barkan D. Alternative and experimental therapies of Mycobacterium abscessus Infections. Int J Mol Sci. 2020; 21(18):6793","DOI":"10.3390\/ijms21186793"},{"issue":"3","key":"7857_CR108","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1055\/s-0038-1651494","volume":"39","author":"L Strnad","year":"2018","unstructured":"Strnad L, Winthrop KL. Treatment of Mycobacterium abscessus complex. Semin Respir Crit Care Med. 2018;39(3):362\u201376.","journal-title":"Semin Respir Crit Care Med"},{"issue":"4","key":"7857_CR109","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 2","key":"7857_CR110","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","volume":"72","author":"CS Haworth","year":"2017","unstructured":"Haworth CS, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1\u201364.","journal-title":"Thorax"},{"issue":"1","key":"7857_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciy867","volume":"68","author":"AH Norris","year":"2019","unstructured":"Norris AH, et al. 2018 Infectious Diseases Society of America Clinical Practice Guideline for the management of outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2019;68(1):1\u20134.","journal-title":"Clin Infect Dis"},{"key":"7857_CR112","unstructured":"Lexicomp. Omadacycline: Drug Infromation. UpToDate. Retrieved 11 Mar 2022."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07857-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T15:52:55Z","timestamp":1701445975000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07857-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7857"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07857-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"19 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing or conflicts of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"874"}}